-
August 20, 2025 Lupin Launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity
-
August 12, 2025 Lupin Announces Licensing Deal for Ranibizumab Biosimilar
-
August 11, 2025 Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States
-
August 5, 2025 Lupin Q1 FY2026 Results
-
July 24, 2025 Lupin Receives US FDA Approvals for Liraglutide and Glucagon Injectable Products
-
July 17, 2025 Lupin Achieves GMP Certification from TGA Australia for Dabhasa API Facility
-
July 16, 2025 Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States
-
July 9, 2025 Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
-
July 4, 2025 Lupin Launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% in the United States
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications